(Axios) – Lawmakers in the House of Representatives on Wednesday are expected to set in motion a massive reordering of how U.S. pharmaceuticals are developed and made, by advancing a contracting ban on five key Chinese research firms. Why it matters: It’s a sign of how trade and national security concerns have spread from steel, semiconductors and TikTok to the life sciences, where U.S. biotechs and drugmakers are highly reliant on China for testing, ingredients and, in some cases, manufacturing. (Read More)